Literature DB >> 8836896

Inhibition of the expression of hepatitis A and B viruses (HAV and HBV) proteins by interferon in a human hepatocarcinoma cell line (PLC/PRF/5).

P Berthillon1, J M Crance, F Leveque, A Jouan, M A Petit, R Deloince, C Trepo.   

Abstract

AIMS/
METHODS: PLC/PRF/5 is a continuous human hepatocarcinoma cell line whose genome contains integrated HBV DNA and which secretes two of the hepatitis B virus envelope proteins (HBs and PreS2). This line is also susceptible to infection by hepatitis A virus and was therefore used to compare the effects of interferon on protein synthesis of these two viruses and to assess the interactions which occur between them during infection.
RESULTS: Results showed that recombinant interferon alpha 2-a inhibited the expression of the two hepatitis B virus envelope antigens (HBs and PreS2) and of the only hepatitis A virus antigen in a dose-dependent fashion. Comparison of the effect of interferon on antigenic protein production of these two viruses, showed stronger inhibition of hepatitis A virus capsid antigen than of hepatitis B virus envelope antigens. Infection with hepatitis A virus also downregulates the expression of the two hepatitis B virus proteins.
CONCLUSIONS: Considering the absence of cytotoxic effects from the doses used, this study confirms the relevance of this cellular model for the study of antiviral cytokines in vitro. It also provides a further rationale for the clinical evaluation of the therapeutic potential of interferons in severe hepatitis cases due either to hepatitis A virus alone or to superinfection of hepatitis B virus carriers by hepatitis A virus.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8836896     DOI: 10.1016/s0168-8278(96)80322-9

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  8 in total

1.  In vitro resistance to interferon of hepatitis B virus with precore mutation.

Authors:  Yan Wang; Lai Wei; Dong Jiang; Xu Cong; Ran Fei; Jiang Xiao; Yu Wang
Journal:  World J Gastroenterol       Date:  2005-02-07       Impact factor: 5.742

2.  Inhibition of hepatitis B virus replication by the interferon-inducible MxA protein.

Authors:  E Gordien; O Rosmorduc; C Peltekian; F Garreau; C Bréchot; D Kremsdorf
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

Review 3.  Immune Mechanisms Underlying Hepatitis B Surface Antigen Seroclearance in Chronic Hepatitis B Patients With Viral Coinfection.

Authors:  Shuling Wu; Wei Yi; Yuanjiao Gao; Wen Deng; Xiaoyue Bi; Yanjie Lin; Liu Yang; Yao Lu; Ruyu Liu; Min Chang; Ge Shen; Leiping Hu; Lu Zhang; Minghui Li; Yao Xie
Journal:  Front Immunol       Date:  2022-05-11       Impact factor: 8.786

Review 4.  Direct-acting Antivirals and Host-targeting Agents against the Hepatitis A Virus.

Authors:  Tatsuo Kanda; Shingo Nakamoto; Shuang Wu; Masato Nakamura; Xia Jiang; Yuki Haga; Reina Sasaki; Osamu Yokosuka
Journal:  J Clin Transl Hepatol       Date:  2015-09-15

5.  Superinfection of hepatitis A virus in hepatocytes infected with hepatitis B virus.

Authors:  Nan Nwe Win; Tatsuo Kanda; Masahiro Ogawa; Shingo Nakamoto; Yuki Haga; Reina Sasaki; Masato Nakamura; Shuang Wu; Naoki Matsumoto; Shunichi Matsuoka; Naoya Kato; Hiroshi Shirasawa; Osamu Yokosuka; Hiroaki Okamoto; Mitsuhiko Moriyama
Journal:  Int J Med Sci       Date:  2019-09-20       Impact factor: 3.738

Review 6.  Co-Occurrence of Hepatitis A Infection and Chronic Liver Disease.

Authors:  Tatsuo Kanda; Reina Sasaki; Ryota Masuzaki; Hiroshi Takahashi; Taku Mizutani; Naoki Matsumoto; Kazushige Nirei; Mitsuhiko Moriyama
Journal:  Int J Mol Sci       Date:  2020-09-02       Impact factor: 5.923

7.  HD-03/ES: A Herbal Medicine Inhibits Hepatitis B Surface Antigen Secretion in Transfected Human Hepatocarcinoma PLC/PRF/5 Cells.

Authors:  Sandeep R Varma; R Sundaram; S Gopumadhavan; Satyakumar Vidyashankar; Pralhad S Patki
Journal:  Hepat Res Treat       Date:  2013-04-10

Review 8.  Hepatitis A: Epidemiology, High-Risk Groups, Prevention and Research on Antiviral Treatment.

Authors:  Marion Migueres; Sébastien Lhomme; Jacques Izopet
Journal:  Viruses       Date:  2021-09-22       Impact factor: 5.048

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.